DAWN NASDAQ
Day One Biopharmaceuticals, Inc.
1W: +0.3%
1M: +0.8%
3M: +80.2%
YTD: +143.3%
1Y: +189.4%
3Y: +69.9%
$21.53
Last traded 2026-04-24 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
12 relationships11
As Filer
counterparties named
1
As Counterparty
mentioned by others
5
Rel. Types
2024-03-07
Earliest Filing
2026-03-06
Latest Filing
partner: 5
acquirer: 2
target: 2
licensee: 1
investor: 1
Counterparties (Filed by DAWN)
11 relationshipsCompanies named in DAWN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Servier Pharmaceuticals LLC | — | acquirer | Parent company entering into a merger agreement to acquire Day One Biopharmaceuticals, Inc. | 2026-03-06 | View |
| Servier Detroit Inc. | — | acquirer | Wholly owned subsidiary of Servier Pharmaceuticals LLC acting as the merger subsidiary. | 2026-03-06 | View |
| Servier S.A.S. | — | partner | French société par actions simplifiée acting as a guarantor for the merger agreement. | 2026-03-06 | View |
| Mersana Therapeutics, Inc. | MRSN | target | Target company acquired in a merger transaction. | 2026-01-06 | View |
| Janssen Biotech, Inc. | — | partner | Counterparty to a Research Collaboration and License Agreement referenced in the filing. | 2026-01-06 | View |
| Mersana Therapeutics, Inc. | MRSN | target | Target company in the merger agreement with Day One Biopharmaceuticals, Inc. | 2025-11-13 | View |
| Janssen Biotech, Inc. | — | partner | Counterparty to a Research Collaboration and License Agreement referenced in the CVR milestones. | 2025-11-13 | View |
| Ipsen Pharma SAS | — | licensee | Exclusive license agreement for commercialization of tovorafenib outside the United States | 2024-07-25 | View |
| Ipsen Biopharmaceuticals, Inc. (USA) | — | investor | Affiliate of Ipsen purchasing shares of common stock in a private placement | 2024-07-25 | View |
| MabCare Therapeutics | — | partner | Exclusive license agreement for MTX-13 (DAY301) anti-body drug conjugate | 2024-06-18 | View |
| Viracta Therapeutics, Inc. | VIRX | partner | Received $8.1 million from the PRV sale proceeds pursuant to a License Agreement. | 2024-05-30 | View |
Mentioned As Counterparty
1 mentionsOther companies that named DAWN in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-04-23 | Termination of Agreement; Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Dire | Acquisition | View |
| 2026-03-09 | Financial Statements and Exhibits | View | |
| 2026-03-06 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-03-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-06 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2025-11-24 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-13 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-11-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-10-30 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-07-30 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-07-25 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR